Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / American depositary shares, each representing one equity share
-
Shares outstanding
-
834,731,296
-
Total 13F shares
-
24,100,699
-
Share change
-
+337,908
-
Total reported value
-
$1,836,647,538
-
Put/Call ratio
-
19%
-
Price per share
-
$76.19
-
Number of holders
-
219
-
Value change
-
+$26,277,340
-
Number of buys
-
113
-
Number of sells
-
98
Institutional Holders of DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY) as of Q2 2024
As of 30 Jun 2024,
DR REDDYS LABORATORIES LTD - American depositary shares, each representing one equity share (RDY) was held by
219 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
24,100,699 shares.
The largest 10 holders included
Robeco Institutional Asset Management B.V., Royal Bank of Canada, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., Aikya Investment Management Ltd, VANGUARD GROUP INC, DIMENSIONAL FUND ADVISORS LP, GOLDMAN SACHS GROUP INC, and STATE STREET CORP.
This page lists
221
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.